Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Binding of hepatocyte growth factor (HGF) to the receptor tyrosine kinase MET is implicated in the malignant process of multiple cancers, making disruption of this interaction a promising therapeutic strategy. However, targeting MET with bivalent antibodies can mimic HGF agonism via receptor dimeriz...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Merchant, Mark, Ma, Xiaolei, Maun, Henry R., Zheng, Zhong, Peng, Jing, Romero, Mally, Huang, Arthur, Yang, Nai-ying, Nishimura, Merry, Greve, Joan, Santell, Lydia, Zhang, Yu-Wen, Su, Yanli, Kaufman, Dafna W., Billeci, Karen L., Mai, Elaine, Moffat, Barbara, Lim, Amy, Duenas, Eileen T., Phillips, Heidi S., Xiang, Hong, Young, Judy C., Vande Woude, George F., Dennis, Mark S., Reilly, Dorothea E., Schwall, Ralph H., Starovasnik, Melissa A., Lazarus, Robert A., Yansura, Daniel G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2013
Gaiak:
PNAS Plus
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3740879/
https://ncbi.nlm.nih.gov/pubmed/23882082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1302725110
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak